The HELIOS-B trial previously showed that vutrisiran (Amvuttra; Alnylam Pharmaceuticals), a gene-silencing therapy that ...
CVRx’s stock has risen nearly 20% after the company revealed that its heart failure device is set to be investigated in an ...
Ozelle, a global innovator in intelligent diagnostics, will showcase its next-generation solution at WHX Labs Dubai 2026 (Feb ...
The highest risk of incident heart failure was seen in individuals with prediabetes combined with either subclinical ...
Orphai Therapeutics Inc. (“Orphai”), a clinical-stage biopharmaceutical company dedicated to advancing novel therapeutics for ...
A collaborative study from the MRC Laboratory of Medical Sciences (LMS) and Imperial College London has found that the protein ACE2 may play a ...
MCTS and Sherwood will hit the field on Thursday, Dec. 4 at 7 p.m. ET. Don't miss out on any of the action with NFHS Network. The NFHS Network gives you access to live high school sports around the ...
NEW ORLEANS -- Despite ongoing scrutiny about its safety, nexiguran ziclumeran (nex-z) still had promising effectiveness data to hold onto. In an update on nex-z's phase I study, the CRISPR-Cas9 gene ...
Background: Elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) levels during the stable phase are associated with poor prognosis in heart failure with preserved ejection fraction (HFpEF).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results